Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways Phase 3 Results Raise Hopes For FDA Approval Of Psilocybin

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
BioPharma Dive

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
AOL

Why Did Compass Pathways Stock Rocket Higher Today?

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...
Stocktwits on MSN

CMPS stock jumps 22% pre-market as Compass sets timeline for new phase 3 depression trial results

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...
FierceBiotech

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...